secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001558370-25-010399
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q2 loss $110M; apitegromab PDUFA Sept 22, 2025; positive EMBRAZE lean mass data
--------------------------------------------------------------------------------

- FDA accepted apitegromab BLA under priority review; PDUFA target action date September 22, 2025.
- Phase 2 EMBRAZE trial: apitegromab + tirzepatide preserved 54.9% more lean mass vs tirzepatide alone (p=0.001).
- Q2 net loss $110M ($0.98/shr) vs $58.5M ($0.60/shr) in prior year; no revenue.
- Cash $295M as of June 30, 2025; expected to fund operations into 2027.
- Preparing for U.S. commercial launch upon potential approval; EMA MAA validated, EU launch anticipated 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/0001558370-25-010399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer